scholarly journals Comparison of Two Different Gnrh Analogs’ Impact on Final Height in Girls with Early Puberty: Triptorelin Acetate vs. Leuprolide Acetate

2020 ◽  
Vol 16 (4) ◽  
pp. 402-408
Author(s):  
S Aka
Keyword(s):  
Final Height ◽  
Leuprolide Acetate ◽  
Early Puberty ◽  
Gnrh Analogs ◽  
Triptorelin Acetate

Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty

2007 ◽  
Vol 93 (11) ◽  
pp. 1456-1462 ◽  
Author(s):  
T Tuvemo ◽  
B Jonsson ◽  
J Gustafsson ◽  
K Albertsson-Wikland ◽  
AS Aronson ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Final Height ◽  
Gnrh Analogue ◽  
Early Puberty

scholarly journals Early puberty in end stage renal failure and renal transplant recipients

2019 ◽  
Vol 32 (6) ◽  
pp. 577-583
Author(s):  
Carmit Avnon Ziv ◽  
Shimrit Tzvi-Behr ◽  
Efrat Ben-Shalom ◽  
Choni Rinat ◽  
Rachel Becker-Cohen ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Precocious Puberty ◽  
Breast Development ◽  
Delayed Puberty ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Early Puberty ◽  
Release Formulation ◽  
Triptorelin Acetate

Abstract Background Delayed puberty and hypogonadism are common in children with chronic kidney disease and in renal transplant recipients, but precocious puberty has rarely been reported in these populations. We describe six girls with precocious and/or early-onset, rapidly progressive puberty before and following renal transplantation. Methods Of 112 children under the age of 18 years (67 boys, 45 girls) who received renal transplants between 2010 and 2018, six girls presented with precocious or rapidly progressive early puberty at ages 6–7/12, 7–2/12, 7–4/12, 8, 8–8/12 and 8–11/12 years. Clinical evaluation included measurements of height, weight, body mass index (BMI), Tanner staging and bone age assessment. Gonadotropin responses to intravenous gonadotropin releasing hormone (GnRH) or intramuscular triptorelin acetate were determined. Results Tanner breast stage 3 was noted at 2–6 years following renal transplantation in five girls, four with preserved kidney function. One girl began puberty before renal transplantation. Peak luteinizing hormone (LH) and follicular stimulating hormone (FSH) levels were 6.5, 20.2, 7.83, 19.1, 9 and 2.2 mIU/mL and 13, 8.3, 8.01, 7.5, 8.1 and 7.7 mIU/mL, respectively. Treatment with an intramuscular slow-release formulation of triptorelin acetate every 4 weeks slowed progression of breast development. Conclusions Although delayed puberty is more common in children with renal disease, precocious puberty can also be seen. Evaluation of growth and puberty by a pediatric endocrinologist should be part of the routine care for all children following kidney transplantation.

scholarly journals Gonadotropin-Releasing Hormone Analogue Treatment in Females with Moderately Early Puberty: No Effect on Final Height

2016 ◽  
Vol 8 (2) ◽  
pp. 211-217 ◽  
Author(s):  
Şenay Savaş-Erdeve ◽  
Zeynep Şıklar ◽  
Bülent Hacıhamdioğlu ◽  
Pınar Kocaay ◽  
Emine Çamtosun ◽  
...  
Keyword(s):  
Final Height ◽  
Gonadotropin Releasing Hormone ◽  
Hormone Analogue ◽  
Early Puberty ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Analogue

scholarly journals LITERATURE REVIEW: ´´THE INFLUENCE OF TREATMENT WITH GnRH ANALOG IN THE FINAL HEIGHT BEFORE AND AFTER EARLY PUBERTY

2021 ◽  
Keyword(s):  
Literature Review ◽  
Standard Treatment ◽  
Final Height ◽  
Maturation Process ◽  
Early Puberty ◽  
Gnrh Analog ◽  
Bone Maturation ◽  
Gnrh Analogues ◽  
Reduced Height ◽  
Before And After

Earl puberty begins with activation of the gonadotrophic axis before 8 years of age in girls and at 9 years of age in boys. One of the main concerns is the height because it accelerates the bone maturation process resulting in reduced height. The standard treatment for precocious puberty is the use of deposits of GnRh analogues with the proposal to minimize the effects on growth. As a result, this literature review is based on demonstrating the effects of using GnRh analogues at the final height. Before and after 8 years of age.

scholarly journals GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome

2010 ◽  
Vol 163 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Valentina Chiavaroli ◽  
Marco Liberati ◽  
Francesco D'Antonio ◽  
Fabio Masuccio ◽  
Rita Capanna ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Final Height ◽  
Model Assessment ◽  
Early Puberty ◽  
Gnrh Analog ◽  
Ovary Syndrome ◽  
Increased Risk ◽  
Significant Difference ◽  
Adult Stature

ObjectiveGNRH analog (GNRHa) therapy has not been supported by beneficial effects on adult stature in girls with early puberty. Furthermore, an increased prevalence of polycystic ovary syndrome (PCOS) has been described in girls treated for central precocious puberty. Women with PCOS are at increased risk of cardiometabolic dysfunctions and infertility. Our aim was to assess GNRHa effectiveness on reaching adult stature and the risk of PCOS in girls with early puberty.DesignLongitudinal study of GNRHa-treated and GNRHa-untreated girls at baseline and at final height.MethodsTwenty-five GNRHa-treated girls and 55 controls were compared. Insulin resistance (IR; homeostasis model assessment of IR (HOMA-IR) and glucose-to-insulin ratio (G/I)), the effect of GNRHa on final height, and the prevalence of PCOS were assessed.ResultsIn GNRHa-treated girls, no significant difference was found between predicted final height and final height, whereas a significant difference was detected in untreated girls (P=0.0001). At final height, GNRHa-treated girls showed higher HOMA-IR and lower G/I (P=0.03 for both) as well as higher DHEAS and androstenedione levels (P=0.02 and P=0.01 respectively) than untreated girls. The prevalence of PCOS and hyperandrogenemia was significantly higher in GNRHa-treated adolescents than in untreated adolescents (36 and 14.5% respectively, P=0.04; 56 and 23.6% respectively, P=0.01). Finally, gonadotropin-suppressive therapy was significantly related to PCOS during adolescence (P=0.03).ConclusionsIn girls with early puberty, GNRHa therapy is associated with the achievement of predicted final height; nevertheless, this treatment seems to act as an independent risk factor for the development of PCOS already during adolescence.

scholarly journals The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours

2004 ◽  
Vol 11 (4) ◽  
pp. 589-602 ◽  
Author(s):  
H K Gleeson ◽  
S M Shalet
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Brain Tumours ◽  
Final Height ◽  
Cranial Irradiation ◽  
Early Puberty ◽  
Gh Therapy ◽  
Childhood Brain Tumours ◽  
The Impact

Survival rates are improving following cancer therapy for childhood brain tumours. There is therefore a growing cohort of survivors at risk of late effects of cancer therapy. Endocrine problems are very common in these patients. The recognition and prompt management of these are essential to prevent further morbidity and impairment of quality of life. Cranial radiation can damage hypothalamic–pituitary function, most frequently affecting GH status; however, higher radiation doses may cause more widespread hypothalamic–pituitary damage. Early puberty secondary to cranial irradiation is now being managed with gonadotrophin-releasing hormone analogues to improve final height. Prompt diagnosis and management of GH deficiency may improve final height outcome; continued GH therapy beyond final height aids the achievement of adult body composition (lean body mass and bone mass) and GH therapy in adulthood improves quality of life. Both cranial irradiation alone and with spinal irradiation can result in radiation damage to the thyroid resulting in hypothyroidism and thyroid nodules, a high proportion of which are malignant. Gonadal damage secondary to spinal irradiation and adjuvant chemotherapy may have long-term consequences including infertility.

Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency

1992 ◽  
Vol 127 (4) ◽  
pp. 307-312 ◽  
Author(s):  
Giuseppe Saggese ◽  
Graziano Cesaretti ◽  
Giuliana Andreani ◽  
Carla Carlotti
Keyword(s):  
Growth Hormone ◽  
Gh Deficiency ◽  
Combined Therapy ◽  
Final Height ◽  
Combined Treatment ◽  
Bone Age ◽  
Height Velocity ◽  
Gnrh Analogue ◽  
Early Puberty ◽  
Gnrh Analogues

In subjects with an isolated GH deficiency the inhibition of puberty by GnRH-analogue administration may be attempted to delay the onset, or to prolong the duration, of pubertal maturation in order to improve final height. We report our experience on the matter in 10 subjects (6M, 4F) suffering from isolated GH deficiency with a chronological age ranging from 6.5 to 10.6 years at diagnosis. After a period of 1–5.1 years of GH treatment, GnRH-analogues (long-acting D-Trp-6-GnRH) were added to GH for 12 months, when six subjects were still prepubertal and four in early puberty. During combined therapy, a regression in pubertal development was shown in three out of four children in early puberty, while serum testosterone or estradiol decreased. Height velocity decreased (from 5.23±1.49 (mean±sd) to 4.12±0.67 cm/year; p<0.02), whereas height sd scores for bone age increased (from −0.75±0.42 to −0.47±0.55; p<0.02). During the year of combined therapy, bone age increased only 0.57±0.27 years. The values for predicted height (TW2 and Bayley-Pinneau method) after combined treatment were also higher than those after treatment with GH alone (p<0.02 and p<0.001, respectively). Our preliminary data showed that the addition of GnRH-analogues to GH in subjects with isolated GH deficiency reduces the effect of GH on height velocity, but determines an improvement in statural prognosis, although a proper answer will not be obtained until final height has been achieved.

Sign in / Sign up

Export Citation Format

Share Document